Anthem Biosciences IPO GMP History
Anthem Biosciences IPO has been listed on July 21, 2025 at a listing price of ₹723.05, against the issue price of ₹570 — a gain of ₹153.05 (+26.85%). The GMP peaked at ₹170 on 21 July 2025 and reached a low of ₹60 on 8 July 2025. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Anthem Biosciences IPO raised ₹3395 Cr. through its IPO at a price band of ₹540 to ₹570 per share, with a lot size of 26 shares. The IPO was open for subscription from 14 Jul 2025 to 16 Jul 2025.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 1:05 AM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 21 Jul 2025 | ₹ 170 | ▲ | 30% | — | — |
| 20 Jul 2025 | ₹ 167 | ▲ | 29% | — | — |
| 19 Jul 2025 | ₹ 156 | ▲ | 27% | — | — |
| 18 Jul 2025 | ₹ 133 | ▼ | 23% | — | — |
| 17 Jul 2025 | ₹ 140 | ▼ | 25% | — | — |
| 16 Jul 2025 | ₹ 148 | ▲ | 26% | — | — |
| 15 Jul 2025 | ₹ 141 | ▲ | 25% | — | — |
| 14 Jul 2025 | ₹ 110 | ▲ | 19% | — | — |
| 12 Jul 2025 | ₹ 98 | ▲ | 17% | — | — |
| 11 Jul 2025 | ₹ 94 | ▼ | 16% | — | — |
| 10 Jul 2025 | ₹ 106 | ▲ | 19% | — | — |
| 09 Jul 2025 | ₹ 90 | ▲ | 16% | — | — |
| 08 Jul 2025 | ₹ 60 | — | 11% | — | — |
Anthem Biosciences IPO dates
Key dates from opening to listing. Today is 10 November.
- Open 14 Jul 2025
- Close 16 Jul 2025
- Allotment 17 Jul 2025
- Refund/credit 18 Jul 2025
- Listing 21 Jul 2025
Anthem Biosciences IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹570 |
|---|---|
| GMP-based estimate (pre-listing) | ₹740 (+29.8%) |
| Listing gain / loss | +₹153.05 per share |
| Listing date | 21 Jul, 2025 |
| Actual listing price | ₹723.05 (+26.85%) |
Is Anthem Biosciences IPO GMP reliable?
Grey market premium for Anthem Biosciences IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Anthem Biosciences IPO full review for a fundamentals-based assessment before making any grey market trades.
Anthem Biosciences IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Anthem Biosciences IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Anthem Biosciences IPO
Anthem Biosciences Limited was incorporated in 2006. It is a contract research, development and manufacturing organisation. Its operations cover drug discovery, development and manufacturing for emerging biotech firms and large pharmaceutical companies.
The company also makes fermentation-based active ingredients. These include probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
On 30 September 2024 it had 196 projects. In the six months to that date it made active ingredients and intermediates for ten commercial molecules, all supported since discovery.
The IPO was entirely an offer for sale of Rs 3,395 crore, so the company received no money from it.
Frequently asked
What is the GMP of Anthem Biosciences IPO?
The current Grey Market Premium (GMP) of Anthem Biosciences IPO is ₹ 170.
What is the Kostak Price of Anthem Biosciences IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Anthem Biosciences IPO is not available.
What is the Subject to Sauda Price of Anthem Biosciences IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Anthem Biosciences IPO?
Anthem Biosciences IPO listed on July 21, 2025 at ₹723.05, against the issue price of ₹570 — a gain of +26.85%.
How did the GMP of Anthem Biosciences IPO trend before listing?
The GMP of Anthem Biosciences IPO was rising in its final days before listing. The GMP peaked at ₹170 on 21 July 2025. View the day-wise table above for the complete GMP history.
Explore Anthem Biosciences IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
